Vijay Kara

GSK, United Kingdom

Poster(s):

• (A-238) Enhancing Post-marketing Quantitative Signal Detection at GSK: A Comprehensive Review
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-240) Enhancing The Meaningfulness of Qualitative Adverse Event Report Reviews Through Incorporation of Quantitative and Qualitative Aspects of Causality Assessment
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-239) Risk-Based Stratification of Pharmacovigilance Data for a Differentiated Approach to Follow-Up
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET